The short answer
Melatonin may add to midazolam-related impairment, but a monitored surgical co-use trial did not show a significant sedation difference. The exact preparation, setting and other medicines matter.
What this answer covers
Oral melatonin preparations, not automatically interchangeable doses or release forms.
- Supplement or preparation
- Melatonin
- Medication ingredient
- midazolam
Both agents can affect alertness
Midazolam is a sedative, and a small daytime melatonin study found impaired performance without midazolam. These individual effects support caution but do not quantify this pair’s added risk.
A direct co-use study found no measured increase
In a thyroidectomy study, patients received melatonin or placebo before anesthesia that included IV midazolam, fentanyl and other drugs. Measured sedation did not significantly differ at the reported times. The multi-drug, monitored setting limits interpretation.
Comparison trials answer another question
Studies that give melatonin instead of midazolam do not establish the safety or added effect of taking both. Oral procedural syrup, injection and nasal rescue also have different uses and dosing.
Review use with the treating team
Disclose melatonin before a procedure or during rescue-plan review. Do not add doses or rely on a short gap as protection. Serious breathing difficulty or inability to wake needs emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional impairment precaution with direct surgical co-use sedation null retained; no exact isolated interaction magnitude or dose/route-independent risk.
- Exact scope
- Oral melatonin preparations, not automatically interchangeable doses or release forms. with Midazolam6960 IN; oral hydrochloride syrup, IV/IM hydrochloride and intranasal midazolam distinguished.
- Medication form and route
- oral medication; intravenous medication; intramuscular medication; intranasal medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed midazolam
CYP3A metabolism, CNS-depressant and respiratory risks; not intended for chronic home sedation.
How this applies: Exact midazolam RxCUI 6960 IN, with stated salt/formulation/route bridge.
Adult oral probe trials not automatic pediatric dosing or nasal/injection interaction magnitude.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed midazolam
Sedation/respiratory and CYP3A interaction precautions.
How this applies: Exact midazolam RxCUI 6960 IN, with stated salt/formulation/route bridge.
Bypasses intestinal absorption; oral exposure findings cannot be assigned unchanged.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed midazolam
CNS-depressant and CYP3A interaction precautions; formulation-specific rescue instructions.
How this applies: Exact midazolam RxCUI 6960 IN, with stated salt/formulation/route bridge.
Not oral procedural dosing; do not delay prescribed seizure rescue to implement an invented herbal gap.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Daytime drowsiness can occur; people with epilepsy need medical supervision when using melatonin.
How this applies: Original source interpreted for midazolam only within the stated preparation and endpoint limits.
Not a direct midazolam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy young adults.
Reaction, response and tracking performance worsened after daytime melatonin.
How this applies: Original source interpreted for midazolam only within the stated preparation and endpoint limits.
Not a direct midazolam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 6: original human study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 50 surgical patients.
No significant difference in measured sedation before induction or10/30minutes after extubation.
How this applies: Original source interpreted for midazolam only within the stated preparation and endpoint limits.
Monitored multi-drug anesthesia, not isolated midazolam interaction or proof of outpatient safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact midazolam article with formulation-specific evidence and uncertainty. |
Article revision: 6dfa5d399d0218c3
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.